Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects
Status:
Unknown status
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and efficacy of 3 loading and
maintenance dose levels of CG100649 administered for 21 days in the treatment of
osteoarthritis pain.